cirm.ca.gov

CIRM approves over $160M to support preclinical and clinical research, advances education opportunities and access to clinical trials

South San Francisco, CA, December 11, 2025 – The California Institute for Regenerative Medicine (CIRM) governing board today approved funding of over $160 million for 16 new research awards to develop ...
cirm.ca.gov

CIRM Announces Recommendations from Strategic Allocation Framework

South San Francisco, CA, September 27, 2024 – The California Institute for Regenerative Medicine (CIRM), one of the world’s largest institutes dedicated to regenerative medicine, announced key ...
cirm.ca.gov

AAV9-Cas13 gene therapy for Angelman syndrome

AAV9-Cas13 gene therapy for Angelman syndrome using a first-in-kind mechanism of action that will safely and permanently restore expression of endogenous UBE3A that is deficient in CNS neurons.
cirm.ca.gov

Stem Cell-Derived Astrocyte Precursor Transplants in Amyotrophic Lateral Sclerosis

Retinal degeneration represents a group of blinding diseases that are increasingly impacting the health and well being of Californians. It is estimated that by 2020, over 450,000 Californians will ...
cirm.ca.gov

Kevin Xu Joins Board of California’s Stem Cell Agency

South San Francisco, CA – The California Institute for Regenerative Medicine (CIRM), the world’s largest institution dedicated to regenerative medicine, is pleased to announce the appointment of Kevin ...
cirm.ca.gov

CIRM approves over $111 million to support discovery and clinical research

The awards approved by the board support three clinical trial (CLIN2) grant applications with a combined approved total of $31M in financial support from CIRM. These grants fund clinical trials for ...
cirm.ca.gov

CIRM approves new $100 million plan to accelerate genetic therapies for patients with rare diseases

South San Francisco, Calif., January 30, 2026 – The California Institute for Regenerative Medicine (CIRM) has approved a new funding program to accelerate therapies for rare diseases, which sets aside ...
cirm.ca.gov

CIRM approves more than $60 million to support clinical and preclinical development awards

South San Francisco, CA, June 25, 2026 – The California Institute for Regenerative Medicine (CIRM) governing board today approved funding of over $40 million for four new preclinical development ...
cirm.ca.gov

CIRM invests more than $42 million in translational-stage research

South San Francisco, CA, Oct. 27, 2023– The California Institute for Regenerative Medicine (CIRM), the world’s largest institution dedicated to regenerative medicine, awarded $42.1 million to fund ...
cirm.ca.gov

Disease Team Therapy Development – Research

The Disease Team Therapy Development Award initiative is an expansion of our original Disease Team Award Initiative. The purpose of the CIRM Disease Team Therapy Development Awards is to advance ...
cirm.ca.gov

CIRM awards $4.7 million for vision loss gene therapy

South San Francisco, CA, May 29, 2025 – The California Institute for Regenerative Medicine (CIRM), one of the world’s largest institutions dedicated to regenerative medicine, awarded $4.7 million to ...
cirm.ca.gov

CIRM awards $27 million to launch novel program designed to bring cell and gene therapies to underserved California communities

South San Francisco, Calif., October 30, 2025 – The California Institute for Regenerative Medicine (CIRM) has approved awarding $27 million through three grants across the state to create a network of ...